Forbes

Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from one‑size‑fits‑all treatment.

Hospital safety isn’t guaranteed. Learn the real risks of medical errors and how patients can protect themselves with smarter healthcare decisions.

Why consumer-directed healthcare hasn’t delivered, and how stronger price signals, better data and new tools could finally make patients better shoppers.

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors to buy stalled drugs and use AI to stress test them faster.

A physician examines whether the FDA's loosening of wellness peptide restrictions means these compounds are actually safe and proven. The answer may surprise you.

Trump promises maximum consumer choice in health care. Yet, he is making it harder to access home -based care favored by older adults and young people with disabilities.

Clinical genome sequencing now delivers genetic diagnoses for about 1 in 4 suspected rare disease patients, guiding targeted care and shaping newborn screening worldwide.

Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to low-income countries. Research ethics are discussed.

Quarterly RNA drug plozasiran turns off a liver gene, sharply lowering life‑threatening pancreatitis attacks in a rare genetic disorder.

In this week’s edition of InnovationRx, we look at the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science & Healthcare list, and more.

UnitedHealth Group earnings next week may signal whether health insurance companies are getting a handle on rising costs dragging down the industry.

A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, side effects and when it could reach patients.

Serially cloned mice hit a genetic “dead end” by generation 58, underscoring that sex evolved for variation, purging harmful mutations and keeping lineages viable.